Geoffrey R. Oxnard

28.8k citations

299 papers · 15.2k indexed · 11 hit papers · h-index 58

Cancer Research top 0.05%
- Cancer Genomics and Diagnostics 155
Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 199
- Lung Cancer Diagnosis and Treatment 34
- Gastric Cancer Management and Outcomes 19
Oncology top 0.1%
- Colorectal Cancer Treatments and Studies 53
- Lung Cancer Research Studies 47
- Cancer Immunotherapy and Biomarkers 29
Pathology and Forensic Medicine top 0.5%
- Genetic factors in colorectal cancer 32
Molecular Biology top 1%

Co-authors: Pasi A. Jänne Cloud P. Paweletz Mark G. Kris Vincent A. Miller Suzanne E. Dahlberg Marc Ladanyi William Pao Kenneth S. Thress
Cited by: Cancer Research Pulmonary and Respiratory Medicine Oncology
Partner nations: United States South Korea United Kingdom

In The Last Decade

Geoffrey R. Oxnard

287 papers receiving 15.0k citations

Hit Papers

11 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
2020 TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
2018 Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
2018 Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
2016 Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016 Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016 MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
2015 Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
2014 Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
2011 Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
2010 Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Peers

Countries citing papers authored by Geoffrey R. Oxnard

Since Specialization

Citations

This map shows the geographic impact of Geoffrey R. Oxnard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey R. Oxnard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey R. Oxnard more than expected).

Fields of papers citing papers by Geoffrey R. Oxnard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey R. Oxnard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey R. Oxnard. The network helps show where Geoffrey R. Oxnard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Geoffrey R. Oxnard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Geoffrey R. Oxnard Line = papers co-authored together Geoffrey R. Oxnard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA Xiaoji Chen,Dong Zhao,Earl Hubbell,Kathryn N. Kurtzman,Geoffrey R. Oxnard,Oliver Venn,Collin Melton,Christina A. Clarke,Rita Shaknovich,Ting Ma,Gerry Meixiong,Michael V. Seiden,Eric A. Klein,Eric T. Fung,Minetta C. Liu	2021	79
2	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations Jian Carrot‐Zhang,Giovanny Soca‐Chafre,Nick Patterson,Aaron R. Thorner,Anwesha Nag,Jacqueline Watson,Giulio Genovese,July Rodríguez,Maya K. Gelbard,Luis Corrales,Yoichiro Mitsuishi,Gavin Ha,Joshua D. Campbell,Geoffrey R. Oxnard,Óscar Arrieta,Andrés F. Cardona,Alexander Gusev,Matthew Meyerson	2020	71
3	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) Erin M. Bertino,Ryan D. Gentzler,Sarah Clifford,Jill Kolesar,Alona Muzikansky,Eric B. Haura,Zofia Piotrowska,D. Ross Camidge,Thomas E. Stinchcombe,Christine Hann,Jyoti Malhotra,Liza C. Villaruz,Cloud P. Paweletz,Christie J. Lau,Lynette M. Sholl,Naoko Takebe,Jeffrey A. Moscow,Geoffrey I. Shapiro,Pasi A. Jänne,Geoffrey R. Oxnard	2020	31
4	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas Susan E. Jorge,Antonio R. Lucena‐Araujo,Hiroyuki Yasuda,Zofia Piotrowska,Geoffrey R. Oxnard,Deepa Rangachari,Mark S. Huberman,Lecia V. Sequist,Susumu Kobayashi,Daniel B. Costa	2018	51
5	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis Yuebi Hu,Bryan C. Ulrich,Julianna Supplee,Yanan Kuang,Patrick H. Lizotte,Nora Feeney,Nicolas Guibert,Mark M. Awad,Kwok‐Kin Wong,Pasi A. Jänne,Cloud P. Paweletz,Geoffrey R. Oxnard	2018	290
6	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients Yuebi Hu,Ryan S. Alden,Justin I. Odegaard,Stephen R. Fairclough,Ruthia Chen,Jennifer Heng,Nora Feeney,Rebecca J. Nagy,Jayshree Shah,Bryan C. Ulrich,Martín Gutiérrez,Richard B. Lanman,Judy E. Garber,Cloud P. Paweletz,Geoffrey R. Oxnard	2017	63
7	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations Helena A. Yu,Alexander I. Spira,Leora Horn,Jared Weiss,Howard West,Giuseppe Giaccone,Tracey L. Evans,Ronan J. Kelly,Bhardwaj Desai,Andrew Krivoshik,Diarmuid Moran,Srinivasu Poondru,Fei Jie,Kouji Aoyama,Anne Keating,Geoffrey R. Oxnard	2017	23
8	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer Magda Bahcall,Taebo Sim,Cloud P. Paweletz,Jyoti D. Patel,Ryan S. Alden,Yanan Kuang,Adrian G. Sacher,Nam Doo Kim,Christine Lydon,Mark M. Awad,Michael T. Jaklitsch,Lynette M. Sholl,Pasi A. Jänne,Geoffrey R. Oxnard	2016	114
9	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial Masahiko Yanagita,Amanda J. Redig,Cloud P. Paweletz,Suzanne E. Dahlberg,Allison O’Connell,Nora Feeney,Myriam Taibi,David Boucher,Geoffrey R. Oxnard,Bruce E. Johnson,Daniel B. Costa,David M. Jackman,Pasi A. Jänne	2016	92
10	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients Cloud P. Paweletz,Adrian G. Sacher,Chris K. Raymond,Ryan S. Alden,Allison O’Connell,Stacy L. Mach,Yanan Kuang,Leena Gandhi,Paul T. Kirschmeier,Jessie M. English,Lee P. Lim,Pasi A. Jänne,Geoffrey R. Oxnard	2015	177
11	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma Antonio Calles,Lynette M. Sholl,Scott J. Rodig,Ashley K. Pelton,Jason L. Hornick,Mohit Butaney,Christine Lydon,Suzanne E. Dahlberg,Geoffrey R. Oxnard,David M. Jackman,Pasi A. Jänne	2015	86
12	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2 Junko Tanizaki,Dalia Ercan,Marzia Capelletti,Michael Dodge,Chunxiao Xu,Magda Bahcall,Erin M. Tricker,Mohit Butaney,Antonio Calles,Lynette M. Sholl,Peter S. Hammerman,Geoffrey R. Oxnard,Kwok‐Kin Wong,Pasi A. Jänne	2015	30
13	Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAbreakdown → Geoffrey R. Oxnard,Cloud P. Paweletz,Yanan Kuang,Stacy L. Mach,Allison O’Connell,Melissa M. Messineo,Jason J. Luke,Mohit Butaney,Paul T. Kirschmeier,David M. Jackman,Pasi A. Jänne	2014	590
14	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations Natasha Rekhtman,Paul K. Paik,Maria E. Arcila,Laura J. Tafe,Geoffrey R. Oxnard,André L. Moreira,William D. Travis,Maureen F. Zakowski,Mark G. Kris,Marc Ladanyi	2012	289
15	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma Mai He,Marzia Capelletti,Khédoudja Nafa,Cai‐Hong Yun,Maria E. Arcila,Vincent A. Miller,Michelle S. Ginsberg,Binsheng Zhao,Mark G. Kris,Michael J. Eck,Pasi A. Jänne,Marc Ladanyi,Geoffrey R. Oxnard	2011	109
16	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes Geoffrey R. Oxnard,Binsheng Zhao,Camelia S. Sima,Michelle S. Ginsberg,Leonard P. James,Robert A. Lefkowitz,Pingzhen Guo,Mark G. Kris,Lawrence H. Schwartz,Gregory J. Riely	2011	118
17	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib Geoffrey R. Oxnard,Yelena Y. Janjigian,Maria E. Arcila,Camelia S. Sima,Samantha L. Kass,Gregory J. Riely,William Pao,Mark G. Kris,Marc Ladanyi,Christopher G. Azzoli,Vincent A. Miller	2011	50
18	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assaybreakdown → Maria E. Arcila,Geoffrey R. Oxnard,Khédoudja Nafa,Gregory J. Riely,Stephen B. Solomon,Maureen F. Zakowski,Mark G. Kris,William Pao,Vincent A. Miller,Marc Ladanyi	2011	476
19	Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutationbreakdown → Geoffrey R. Oxnard,Maria E. Arcila,Camelia S. Sima,Gregory J. Riely,Juliann Chmielecki,Mark G. Kris,William Pao,Marc Ladanyi,Vincent A. Miller	2010	485
20	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development Binsheng Zhao,Geoffrey R. Oxnard,Chaya S. Moskowitz,Mark G. Kris,William Pao,Pingzhen Guo,Valerie W. Rusch,Marc Ladanyi,Naiyer A. Rizvi,Lawrence H. Schwartz	2010	82

About Geoffrey R. Oxnard

Geoffrey R. Oxnard is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 299 papers that have together received 15.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (199 papers), Cancer Genomics and Diagnostics (155 papers), Colorectal Cancer Treatments and Studies (53 papers), Lung Cancer Research Studies (47 papers), Lung Cancer Diagnosis and Treatment (34 papers), Genetic factors in colorectal cancer (32 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Gastric Cancer Management and Outcomes (19 papers). The work is most often cited by research in Cancer Research (6.3k citations), Pulmonary and Respiratory Medicine (11.1k citations) and Oncology (8.5k citations). Geoffrey R. Oxnard has collaborated with scholars based in United States, South Korea and United Kingdom. Frequent co-authors include Pasi A. Jänne, Cloud P. Paweletz, Mark G. Kris, Vincent A. Miller, Suzanne E. Dahlberg, Marc Ladanyi, William Pao, Kenneth S. Thress, Maria E. Arcila and David M. Jackman.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact